Home › Companies › ESPERION THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ESPERION THERAPEUTICS INC.’s Form 8-K, filed May 28, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 23, 2024: 6 items on ESPERION THERAPEUTICS INC.’s Form 8-K, filed May 28, 2024: 6 passed (calculated).
Notable dissent: 1 other board item (25.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ESPERION THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ESPERION THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Antonio M. Gotto Jr., M.D., D.Phil. | 87,858,914 | -- | -- | 7,863,580 | 44,073,687 | 92% | Passed (calculated) | — |
| Elect Director: Nicole Vitullo | 90,961,988 | -- | -- | 4,760,506 | 44,073,687 | 95% | Passed (calculated) | — |
| Company's stockholders approved Proposal 2. | 70,745,164 | 24,537,427 | 439,903 | -- | 44,073,687 | 74% | Passed (calculated) | — |
| Company's stockholders approved Proposal 3. | 136,839,607 | 2,422,428 | 534,146 | -- | -- | 98% | Passed (calculated) | — |
| Company's stockholders approved Proposal 4. | 88,126,993 | 7,007,381 | 588,120 | -- | 44,073,687 | 93% | Passed (calculated) | — |
| Company's stockholders approved Proposal 5. | 88,771,186 | 6,425,073 | 526,235 | -- | 44,073,687 | 93% | Passed (calculated) | — |
Source: ESPERION THERAPEUTICS INC., Form 8-K, filed with the SEC on May 28, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
110 asset managers disclosed a vote on at least one ESPERION THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ESPERION THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Antonio M. Gotto Jr., M.D., D.Phil.
ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Antonio M. Gotto Jr., M.D., D.Phil.”): 87,858,914 for, 7,863,580 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 14,469,987 for, 102,309 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 42,500 | Withhold |
| Russell Investments | 38,499 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 29,151 | Withhold |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 604 | 0 | 0 | 16,927 | Withhold |
| Jacob Funds Inc. | 14,725 | 0 | 0 | 0 | For |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 9,340 | Withhold |
| Invesco | 0 | 0 | 0 | 2,623 | Withhold |
| John Hancock | 0 | 0 | 0 | 1,768 | Withhold |
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Nicole Vitullo
ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nicole Vitullo”): 90,961,988 for, 4,760,506 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 14,572,296 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 42,500 | 0 | 0 | 0 | For |
| Russell Investments | 38,499 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 29,151 | 0 | 0 | 0 | For |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 17,531 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 14,725 | 0 | 0 | 0 | For |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 9,340 | 0 | 0 | 0 | For |
| Invesco | 2,623 | 0 | 0 | 0 | For |
| John Hancock | 1,768 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 42,500 | 0 | 0 | 0 | For |
| Russell Investments | 38,499 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 29,151 | 0 | 0 | 0 | For |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 17,531 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 14,725 | 0 | 0 | 0 | For |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 9,340 | 0 | 0 | 0 | For |
| Invesco | 2,623 | 0 | 0 | 0 | For |
| John Hancock | 1,768 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 42,500 | 0 | 0 | 0 | For |
| Russell Investments | 38,499 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 29,151 | 0 | 0 | 0 | For |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 17,531 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 14,725 | 0 | 0 | 0 | For |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 9,340 | 0 | 0 | 0 | For |
| Invesco | 2,623 | 0 | 0 | 0 | For |
| John Hancock | 1,768 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
76% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 42,500 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 38,499 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 29,151 | 0 | 0 | 0 | For |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 17,531 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 13,275 | 1,450 | 0 | 0 | Mixed |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 9,340 | 0 | 0 | 0 | For |
| Invesco | 2,623 | 0 | 0 | 0 | For |
| John Hancock | 1,768 | 0 | 0 | 0 | For |
Fund voting reports, all 18 managers: 14,532,347 for, 39,949 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 | 16,213,933 | 0 | 0 | Against |
| Woodline Partners LP | 10,810,492 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 7,535,627 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 7,456,000 | 0 | 0 | 0 | For |
| DE Shaw | 4,357,270 | 0 | 0 | 0 | For |
| Citadel | 2,571,374 | 0 | 0 | 0 | For |
| Two Sigma | 2,132,172 | 0 | 0 | 0 | For |
| BlackRock | 1,980,687 | 269 | 0 | 0 | For |
| Goldman Sachs | 1,600,250 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,597,542 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 1,425,133 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 741,998 | 0 | 0 | 0 | For |
| Wellington | 0 | 445,605 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 316,961 | 0 | 0 | 0 | For |
| State Street | 303,636 | 0 | 0 | 0 | For |
| Corient Private Wealth LLC | 239,000 | 5,000 | 0 | 0 | For |
| NJ State Employees Deferred Compensation Plan | 195,125 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 184,020 | 0 | 0 | Against |
| HighTower Advisors, LLC | 181,751 | 0 | 0 | 0 | For |
| Northern Trust | 162,823 | 0 | 0 | 0 | For |
| UBS | 142,418 | 0 | 0 | 0 | For |
| JPMorgan | 114,352 | 0 | 0 | 0 | For |
| PINNACLE ASSOCIATES LTD | 99,958 | 0 | 0 | 0 | For |
| Point72 | 68,788 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 65,225 | 0 | 0 | 0 | For |
Institutional-manager reports, all 99 managers: 43,180,329 for, 18,423,039 against. Showing the 25 largest; every one is in the interactive database (link above).
100% of fund votes cast · no official result
The 2 asset managers below reported 1,335,654 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 1,335,595 | 0 | 0 | 0 | For |
| TD ASSET MANAGEMENT INC | 59 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 6,356,989 | 0 | 0 | 0 | For |
| Vanguard | 6,295,387 | 0 | 0 | 0 | For |
| JPMorgan | 1,197,072 | 0 | 0 | 0 | For |
| Fidelity | 242,843 | 0 | 0 | 0 | For |
| Lincoln Financial | 108,919 | 0 | 0 | 0 | For |
| BlackRock | 83,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 47,541 | 0 | 0 | 0 | For |
| Charles Schwab | 44,438 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 42,500 | 0 | 0 | 0 | For |
| Russell Investments | 38,499 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 29,151 | 0 | 0 | 0 | For |
| Voya | 25,782 | 0 | 0 | 0 | For |
| Nationwide | 17,531 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 14,725 | 0 | 0 | 0 | For |
| Equitable | 13,871 | 0 | 0 | 0 | For |
| Victory Capital | 9,340 | 0 | 0 | 0 | For |
| Invesco | 2,623 | 0 | 0 | 0 | For |
| John Hancock | 1,768 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,460,293 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | WASATCH FUNDS TRUST | 3.36% |
| 2 | Vanguard | 3.32% |
| 3 | JPMorgan | 0.63% |
| 4 | Fidelity | 0.13% |
| 5 | Lincoln Financial | 0.06% |
| 6 | BlackRock | 0.04% |
| 7 | AIG/SunAmerica | 0.03% |
| 8 | Charles Schwab | 0.02% |
| 9 | Blackstone Alternative Investment Funds | 0.02% |
| 10 | Russell Investments | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 8.56% |
| 2 | Woodline Partners LP | 5.71% |
| 3 | WASATCH ADVISORS LP | 3.98% |
| 4 | GREAT POINT PARTNERS LLC | 3.94% |
| 5 | DE Shaw | 2.30% |
| 6 | Citadel | 1.36% |
| 7 | Two Sigma | 1.13% |
| 8 | BlackRock | 1.05% |
| 9 | Goldman Sachs | 0.84% |
| 10 | PLATINUM INVESTMENT MANAGEMENT LTD | 0.84% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 14,833,791 | 7.83% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 12,092,449 | 6.38% | Form 13F, quarter ended March 31, 2024 |
| BB Biotech AG | 9,194,064 | 4.85% | Schedule 13G, filed January 24, 2024 |
| Millennium Management | 5,681,744 | 3.00% | Form 13F, quarter ended March 31, 2024 |
| D.E. Shaw | 5,143,486 | 2.71% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 4,055,626 | 2.14% | Form 13F, quarter ended March 31, 2024 |
| Two Sigma | 3,975,560 | 2.10% | Form 13F, quarter ended March 31, 2024 |
| Citadel Advisors | 3,747,710 | 1.98% | Form 13F, quarter ended March 31, 2024 |
| Renaissance Technologies | 2,116,500 | 1.12% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,753,193 | 0.93% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 189,460,293 shares outstanding, as reported by ESPERION THERAPEUTICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ESPERION THERAPEUTICS INC.'s shareholder meeting held May 23, 2024, in the 2023-2024 proxy season, 110 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 360 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ESPERION THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve the non-binding advisory resolution on the compensation of our named executive… — the reporting funds and managers cast 76% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ESPERION THERAPEUTICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ESPERION THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ESPERION THERAPEUTICS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/esperion-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.